|
|
|
|
This on-demand webinar explores practical manufacturing considerations behind in vivo CAR-T and gene editing, including modality selection, viral vector and RNA LNP platform requirements, CMC strategy, and the steps needed to move complex therapies toward clinical readiness.
|
|
|
|
|
Producer cell lines are emerging as a more scalable and consistent alternative to transient manufacturing — but transitioning platforms introduces key comparability considerations. This white paper explores how analytical comparability, risk assessment, and bridging strategies can support a smooth and compliant transition.
|
|
|
|
|
Growing demand for lentiviral vectors is driving the need for robust and scalable production approaches. This technical note highlights how a ready‑to‑use platform technology supports efficient development, shortens timelines to GMP, and enables processes suitable for large‑scale manufacturing.
|
|
|
|
|
|
|
|
Modernizing mRNA Quality Control
|
Learn how Lonza is advancing GMP mRNA quality control through direct RNA sequencing, machine learning, and multi attribute analysis, helping simplify complex testing workflows and support faster, more informed release decisions for mRNA therapeutics.
|
|
|
|
|
|
|
